Amivantamab news

All news on Amivantamab (also known as RYBREVANT): plants, production capacities, investments and involved companies.

31 May 2026

Johnson & Johnson: RYBREVANT FASPRO shows durable responses in advanced head and neck cancer

Phase 1b/2 OrigAMI-4: subcutaneous amivantamab + hyaluronidase achieved 42% ORR (15% CR) in pretreated recurrent/metastatic HNSCC; median DOR not reached (11.8 mo FU); manageable safety.
23 February 2026

Johnson & Johnson's RYBREVANT® Approved for New Dosing Options in EGFR-Mutated Lung Cancer

European Commission approves subcutaneous RYBREVANT® for flexible dosing in advanced EGFR-mutated NSCLC, offering reduced clinic time and fewer reactions.
19 February 2026

Johnson & Johnson's Rybrevant Faspro™ Shows 56% Response Rate in First-Line Head and Neck Cancer

The OrigAMI-4 study shows amivantamab with immunotherapy offers durable antitumor activity in recurrent/metastatic head and neck cancer, improving outcomes over current treatments.

Who will be producing Amivantamab in the future?

Find out with chemXplore Alpha

Learn more